Statistical modeling and verification for the synthesis of median survival time in multilevel meta-analysis of survival data

Objective: Past meta-analyses of survival data have been over simplistic because of restricting to proportional hazard model, lackof intuitive results, and potential omitting information. These had the potential to recommend sub-optimal policies. Here wedevelop multilevel methods for combining median survival times (MSTs) for meta-analysis of survival data. Methods: We used simulated data to test and verify the synthesis model we developed. We generated the study-level data to fit multilevel model and individual patient data to calculate gold standard. We then used the Bland-Altman method and the relativechange from the gold standard to evaluate the fit of the models. Examples were presented in a meta-analysis to illustrate the feasibility of the models. Results: We generated eight sets of simulated datasets of different number of studies and sample size. We established themulti-level fixed and random effect models to pool the MSTs. The test of the fitness of the model showed that the means ofdifference (d) for all simulated datasets between the calculated values and the gold standards are no more than -0.230 and -0.329days and the largest 95% CIs of d are -3.823 3.364 and -3.936 3.278 days respectively. At least 91.9% and 92.3% of the difference between the estimated values and the gold standards are small. The real examples of a meta-analysis were provided with combined MSTs along with pooled HR. Conclusions: The multilevel models of synthesizing MSTs in survival data AD meta-analysis were verified with good fitting effects and provide more intuitive information.

[1]  M. Parmar,et al.  Meta-analysis of the literature or of individual patient data: is there a difference? , 1993, The Lancet.

[2]  M. S. Patel,et al.  An introduction to meta-analysis. , 1989, Health Policy.

[3]  Roy S Herbst,et al.  Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Parmar,et al.  Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. , 1998, Statistics in medicine.

[5]  W. Evans Gefitinib does not improve survival when combined with paclitaxel and carboplatin chemotherapy in people with advanced non-small-cell lung cancer. , 2004, Cancer treatment reviews.

[6]  Bruce E. Johnson,et al.  Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). , 2010 .

[7]  R M Turner,et al.  Multilevel models for meta-analysis, and their application to absolute risk differences , 2001, Statistical methods in medical research.

[8]  G. Giaccone,et al.  Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  D. Robinson,et al.  Modelling survival data in medical research, second edition , 2004 .

[10]  D. Altman,et al.  Measuring agreement in method comparison studies , 1999, Statistical methods in medical research.

[11]  M. Cheung Computing effect sizes for meta‐analysis , 2015 .

[12]  W. D. Ray 4. Modelling Survival Data in Medical Research , 1995 .

[13]  Multi-level model synthesis of median survival time in meta-analysis. , 2015, Epidemiology.

[14]  J. Zang,et al.  Synthesis of median survival time in meta-analysis. , 2013, Epidemiology.

[15]  Xin Li,et al.  TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  G. Giaccone,et al.  SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Mark C Simmonds,et al.  Meta-analysis of individual patient data from randomized trials: a review of methods used in practice , 2005, Clinical trials.

[18]  J. Milanowski,et al.  Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  M. Sydes,et al.  Practical methods for incorporating summary time-to-event data into meta-analysis , 2007, Trials.

[20]  S. Sharp,et al.  Explaining heterogeneity in meta-analysis: a comparison of methods. , 1999 .

[21]  D. Altman,et al.  STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT , 1986, The Lancet.

[22]  Richard D Riley,et al.  Evidence synthesis combining individual patient data and aggregate data: a systematic review identified current practice and possible methods. , 2007, Journal of clinical epidemiology.

[23]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[24]  Stefan Michiels,et al.  Meta-analysis when only the median survival times are known: A comparison with individual patient data results , 2005, International Journal of Technology Assessment in Health Care.

[25]  R. Singh,et al.  Survival analysis in clinical trials: Basics and must know areas , 2011, Perspectives in clinical research.

[26]  T. Mok,et al.  Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Theo Stijnen,et al.  Meta‐analysis of summary survival curve data , 2008, Statistics in medicine.

[28]  L. Hedges,et al.  Introduction to Meta‐Analysis , 2009, International Coaching Psychology Review.

[29]  B. Milleron,et al.  Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study. , 2010 .

[30]  J. Pignon,et al.  Meta-analyses of randomised clinical trials in oncology. , 2001, The Lancet. Oncology.

[31]  G. Giaccone,et al.  Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. , 2010, The Lancet. Oncology.

[32]  V. Torri,et al.  A double-blind, randomized, placebo-controlled phase III intergroup study of gefitinib (G) in patients (pts) with advanced NSCLC, non-progressing after first-line platinum-based chemotherapy (EORTC 08021-ILCP 01/03). , 2010 .

[33]  C D Naylor,et al.  Meta-analysis of controlled clinical trials. , 1989, The Journal of rheumatology.